Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Siim Pauklin wins funding from Pancreatic Cancer UK to accelerate the detection of this devastating disease.

Survival for pancreatic cancer is very low – less than 3% people survive for five years following diagnosis – and this has not improved in decades. The vagueness of pancreatic cancer symptoms such as back pain, weight loss, and indigestion, and the absence of effective early detection tests frequently leads to late diagnosis of this disease. Indeed, 53% of patients are currently diagnosed with stage 4 disease, after the cancer has already metastasised, making it more difficult to treat successfully.

Siim Pauklin (Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences) has been awarded funding from the Pancreatic Cancer UK Research Innovation Fund to develop a test for early stage disease. It is known that cancer cells, including pancreatic cancer cells, shed DNA into the blood. Dr Pauklin aims to identify a pancreatic cancer-specific DNA signature that will allow the presence of pancreatic cancer in the body to be detected using a blood test.

 

Read more about this project on the Pancreatic Cancer UK website.

Similar stories

Funded DPhil studentships in early detection available - apply now for October 2023 entry

Oxford research groups are recruiting DPhil candidates for the funded DPhil in Cancer Science commencing in October 2023.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.